Kamada (KMDA) Income from Non-Controlling Interests (2019 - 2022)

Kamada (KMDA) posted quarterly Income from Non-Controlling Interests of -$108000.0 for Q1 2022, down 47.95% year-on-year from -$207473.7 in Q1 2021, and down 47.95% on a QoQ basis from -$73000.0 in Q1 2021.

Kamada (KMDA) Income from Non-Controlling Interests (2019 - 2022) Analysis & Trends

Kamada (KMDA) has reported Income from Non-Controlling Interests for 4 consecutive years, with -$108000.0 the latest figure, recorded in Q1 2022.

  • Quarterly Income from Non-Controlling Interests fell 47.95% year-over-year to -$108000.0 in Q1 2022, while the trailing twelve-month figure through Mar 2022 was $134000.0 (changed N/A YoY) and the FY2021 annual result came in at $185000.0, down 78.88% from the prior year.
  • Income from Non-Controlling Interests retreated to -$108000.0 in Q1 2022 per KMDA's latest filing, from -$73000.0 in the prior quarter.
  • Over the last five years, Income from Non-Controlling Interests for KMDA reached as high as $241000.0 in Q1 2020 and fell as low as -$108000.0 in Q1 2022.
  • A 4-year average of $33500.0 and a median of $500.0 in 2019 frame the typical range for Income from Non-Controlling Interests.
  • Annual changes were most pronounced in 2020 — Income from Non-Controlling Interests jumped 225.68% — and 2021, when it plunged 130.29%.
  • Year by year, Income from Non-Controlling Interests stood at $74000.0 in 2019, then soared by 225.68% to $241000.0 in 2020, then tumbled by 130.29% to -$73000.0 in 2021, then sank by 47.95% to -$108000.0 in 2022.
  • According to Business Quant data, Income from Non-Controlling Interests over the past three periods registered -$108000.0, -$73000.0, and $241000.0 for Q1 2022, Q1 2021, and Q1 2020 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Inc. Minority (Qtr)
1 Haleon 89.28 Bn 87.42 Bn - -
2 Teva Pharmaceutical Industries 35.85 Bn 32.11 Bn 1.97 Bn -
3 Zoetis 32.48 Bn 30.54 Bn 1.62 Bn -
4 Takeda Pharmaceutical 27.52 Bn 23.46 Bn 4.39 Bn 395,346.10
5 United Therapeutics 23.16 Bn 21.01 Bn 648.10 Mn -
6 RedHill Biopharma 21.76 Bn 21.76 Bn - -
7 Viatris 20.33 Bn 18.53 Bn 1.16 Bn -
8 Neurocrine Biosciences 17.74 Bn 16.43 Bn 800.70 Mn -12.70 Mn
9 Elanco Animal Health 12.64 Bn 12.21 Bn 785.00 Mn -
10 Kamada 402.37 Mn 329.22 Mn 19.12 Mn -

Historic Data

Download Data
DateValue
Mar 31, 2022 -108,000.00
Mar 31, 2021 -73,000.00
Mar 31, 2020 241,000.00
Mar 31, 2019 74,000.00